Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lalitha K. Shankar, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V. Knopp, Richard L. Wahl, Benjamin M. Ellingson, Nathan C. Hall, Martin J. Yaffe, Alexander J. Towbin, Michael D. Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L. Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M. Wu, David Leung, Elisabeth G.E. de VriesYing Tang, Gillian Beach, Steven A. Reeves

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools—including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents—offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

Original languageEnglish
Pages (from-to)e133-e143
JournalThe Lancet Oncology
Volume24
Issue number3
DOIs
StatePublished - Mar 2023

Fingerprint

Dive into the research topics of 'Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop'. Together they form a unique fingerprint.

Cite this